ClinicalTrials.gg
Not yet recruitingNCT07531992HRV-BPUpdated Apr 15, 2026

Comparison of Heart Rate Variability Analysis Durations and Their Relationship With Blood Pressure

An interventional study of Heart Rate Variability and Blood Pressure Assessment in Heart Rate Variability, sponsored by Sinop University. Not yet recruiting at 1 site in Turkey (Türkiye). Open to participants aged 18 Years to 40 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2026-04-15.

Sponsored by Sinop University · Not applicable, Interventional, and Other

How we know

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
40
Allocation
Not applicable
Ages
18 Years to 40 Years
Sex
All
01

Study summary

This observational study aims to compare heart rate variability (HRV) parameters obtained from different analysis durations in healthy adults and to examine how these parameters relate to resting blood pressure values. HRV is a noninvasive measure commonly used to assess autonomic nervous system activity. Standard short-term HRV analysis is typically based on 5-minute recordings, but shorter and longer analysis durations are also used in research and practice. This study will evaluate whether HRV values derived from 1-minute, 5-minute, 10-minute, and 20-minute analysis windows differ from one another and whether their relationships with systolic blood pressure, diastolic blood pressure, and mean arterial pressure change according to analysis duration. Participants will attend a single study visit. After a rest period, resting blood pressure and pulse will be measured, and a continuous HRV recording will be obtained using a chest strap device. The study is designed to provide methodological information on the comparability of different HRV analysis durations under the same physiological conditions.

Read the detailed description

Heart rate variability (HRV) is widely used as a noninvasive indicator of autonomic nervous system regulation and provides information about sympathetic-parasympathetic balance. Although 5-minute recordings are commonly recommended for short-term HRV assessment, interest has increased in ultra-short and longer analysis durations because they may improve feasibility and reduce participant burden. However, the extent to which HRV parameters derived from different analysis durations agree with one another remains uncertain, particularly when comparing time-domain and frequency-domain measures. In addition, limited research has systematically examined whether the relationship between HRV and blood pressure varies according to HRV analysis duration. This study is intended to address that methodological gap.

This is a single-center, single-visit, observational methodological comparison study in healthy adults. Eligible participants will complete a sociodemographic data form and will undergo resting hemodynamic assessment and HRV recording under standardized conditions. Measurements will be performed in a quiet environment after an adaptation period. Resting systolic blood pressure, diastolic blood pressure, and pulse will be measured using an automated oscillometric upper-arm blood pressure monitor. RR interval data will then be recorded continuously using the Polar H10 chest strap and analyzed using Kubios HRV software.

HRV analyses will be derived from a single continuous recording using predefined analysis windows of 1 minute, 5 minutes, 10 minutes, and 20 minutes. These windows will be extracted from the same physiological recording in order to minimize time-related variation and allow direct comparison across durations. Time-domain and frequency-domain HRV parameters will be calculated, and the agreement and comparability of measurements across analysis durations will be evaluated. Associations between HRV parameters and resting hemodynamic variables, including systolic blood pressure, diastolic blood pressure, mean arterial pressure, and pulse, will also be examined according to analysis duration.

The study is expected to provide methodological evidence regarding whether shorter or longer HRV analysis durations can be interpreted consistently relative to standard short-term recordings. The findings may help improve protocol standardization and support more accurate physiological and clinical interpretation of HRV data obtained under resting conditions.

02

Conditions studied

  • Heart Rate Variability

Keywords

  • Heart Rate Variability
  • HRV
  • Autonomic Nervous System
03

In context

Lead sponsor

Sinop University is the lead sponsor of 35 studies on the registry; 13 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years to 40 Years
Sexes eligible
All
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Healthy adults aged 18 to 40 years
  • Willing and able to provide
  • Able to comply with pre-assessment instructions, including restrictions related to caffeine intake and strenuous physical activity
  • No condition preventing heart rate variability and blood pressure measurements

Exclusion criteria

Exclusion Criteria:

  • History of diagnosed cardiovascular, neurological, or autonomic nervous system disease
  • Known arrhythmia or pacemaker use
  • Regular use of medications that may affect heart rate variability, such as beta blockers or antiarrhythmic drugs
  • Acute infection, fever, or any condition affecting general health status on the day of assessment
  • Severe motion artifact during measurement or technically unusable recordings
Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

05

Study design

Phase
Not applicable
Primary purpose
Other
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
40 participants (estimated)

Study arms

  • Experimental
    Healthy Adult Assessment Group

    Healthy adult participants will attend a single study visit and undergo resting hemodynamic and heart rate variability (HRV) assessment under standardized conditions. After an adaptation period, systolic blood pressure, diastolic blood pressure, and pulse will be measured using an automated oscillometric blood pressure monitor. A continuous RR interval recording will then be obtained using the Polar H10 chest strap. HRV parameters will be derived from predefined 1-minute, 5-minute, 10-minute, and 20-minute analysis windows extracted from the same recording for methodological comparison.

    Other: Heart Rate Variability and Blood Pressure Assessment

Interventions

  • OtherHeart Rate Variability and Blood Pressure Assessment

    Participants will complete a single-visit resting physiological assessment under standardized conditions. After an adaptation period, systolic blood pressure, diastolic blood pressure, and pulse will be measured using an automated oscillometric upper-arm blood pressure monitor. Continuous RR interval data will then be recorded using the Polar H10 chest strap and analyzed with Kubios HRV software. Heart rate variability parameters will be calculated from predefined 1-minute, 5-minute, 10-minute, and 20-minute analysis windows extracted from the same continuous recording for methodological comparison.

06

What researchers measure

Primary outcomes

  1. RMSSD Across Different Analysis Durations

    Root mean square of successive differences (RMSSD), in milliseconds (ms), calculated from predefined 1-minute, 5-minute, 10-minute, and 20-minute analysis windows extracted from the same continuous resting RR interval recording obtained under standardized resting conditions.

    Time frame: Baseline, during a single study visit

  2. SDNN Across Different Analysis Durations

    Standard deviation of normal-to-normal intervals (SDNN), in milliseconds (ms), calculated from predefined 1-minute, 5-minute, 10-minute, and 20-minute analysis windows extracted from the same continuous resting RR interval recording obtained under standardized resting conditions.

    Time frame: Baseline, during a single study visit

  3. Low-Frequency Power Across Different Analysis Durations

    Low-frequency (LF) power, in ms\^2, calculated from predefined 1-minute, 5-minute, 10-minute, and 20-minute analysis windows extracted from the same continuous resting RR interval recording obtained under standardized resting conditions.

    Time frame: Baseline, during a single study visit

  4. High-Frequency Power Across Different Analysis Durations

    High-frequency (HF) power, in ms\^2, calculated from predefined 1-minute, 5-minute, 10-minute, and 20-minute analysis windows extracted from the same continuous resting RR interval recording obtained under standardized resting conditions.

    Time frame: Baseline, during a single study visit.

  5. LF/HF Ratio Across Different Analysis Durations

    Low-frequency/high-frequency (LF/HF) ratio calculated from predefined 1-minute, 5-minute, 10-minute, and 20-minute analysis windows extracted from the same continuous resting RR interval recording obtained under standardized resting conditions.

    Time frame: Baseline, during a single study visit.

Secondary outcomes

  1. Agreement of RMSSD Across Different Analysis Durations

    Agreement of RMSSD values, in milliseconds (ms), obtained from 1-minute, 5-minute, 10-minute, and 20-minute analysis windows extracted from the same continuous resting RR interval recording, assessed using intraclass correlation coefficients and Bland-Altman analysis.

    Time frame: Baseline, during a single study visit

  2. Agreement of SDNN Across Different Analysis Durations

    Agreement of SDNN values, in milliseconds (ms), obtained from 1-minute, 5-minute, 10-minute, and 20-minute analysis windows extracted from the same continuous resting RR interval recording, assessed using intraclass correlation coefficients and Bland-Altman analysis.

    Time frame: Baseline, during a single study visit

  3. Agreement of Low-Frequency Power Across Different Analysis Durations

    Agreement of low-frequency (LF) power values, in ms\^2, obtained from 1-minute, 5-minute, 10-minute, and 20-minute analysis windows extracted from the same continuous resting RR interval recording, assessed using intraclass correlation coefficients and Bland-Altman analysis.

    Time frame: Baseline, during a single study visit

  4. Agreement of High-Frequency Power Across Different Analysis Durations

    Agreement of high-frequency (HF) power values, in ms\^2, obtained from 1-minute, 5-minute, 10-minute, and 20-minute analysis windows extracted from the same continuous resting RR interval recording, assessed using intraclass correlation coefficients and Bland-Altman analysis.

    Time frame: Baseline, during a single study visit

  5. Agreement of LF/HF Ratio Across Different Analysis Durations

    Agreement of low-frequency/high-frequency (LF/HF) ratio values obtained from 1-minute, 5-minute, 10-minute, and 20-minute analysis windows extracted from the same continuous resting RR interval recording, assessed using intraclass correlation coefficients and Bland-Altman analysis.

    Time frame: Baseline, during a single study visit

  6. Correlation Between RMSSD and Resting Systolic Blood Pressure

    Correlation between RMSSD, in milliseconds (ms), and resting systolic blood pressure, in mmHg, measured under standardized resting conditions during the same study visit.

    Time frame: Baseline, during a single study visit

  7. Correlation Between RMSSD and Resting Diastolic Blood Pressure

    Correlation between RMSSD, in milliseconds (ms), and resting diastolic blood pressure, in mmHg, measured under standardized resting conditions during the same study visit.

    Time frame: Baseline, during a single study visit

  8. Correlation Between RMSSD and Mean Arterial Pressure

    Correlation between RMSSD, in milliseconds (ms), and mean arterial pressure, in mmHg, calculated from resting blood pressure measurements obtained during the same study visit.

    Time frame: Baseline, during a single study visit

  9. Resting Systolic Blood Pressure

    Resting systolic blood pressure, in mmHg, measured under standardized resting conditions before HRV recording.

    Time frame: Baseline, during a single study visit

  10. Resting Diastolic Blood Pressure

    Resting diastolic blood pressure, in mmHg, measured under standardized resting conditions before HRV recording.

    Time frame: Baseline, during a single study visit

  11. Mean Arterial Pressure

    Mean arterial pressure, in mmHg, calculated from resting systolic and diastolic blood pressure measurements obtained under standardized resting conditions before HRV recording.

    Time frame: Baseline, during a single study visit

  12. Resting Pulse Rate

    Resting pulse rate, in beats per minute, measured under standardized resting conditions before HRV recording.

    Time frame: Baseline, during a single study visit

07

Study locations

1 site
  • Artvin Coruh University, Artvin Vocational School, Disabled Care and Rehabilitation Laboratory, Artvin,
    Artvin, Turkey (Türkiye)
    • Ömer Dicle Kızıl, MSc · Contactomerdiclekizil@gmail.com · +90 541 523 36 91
    • Ömer Dicle Kızıl, MSc · Sub investigator
08

References and documents

Publications

  • Munoz ML, van Roon A, Riese H, Thio C, Oostenbroek E, Westrik I, de Geus EJ, Gansevoort R, Lefrandt J, Nolte IM, Snieder H. Validity of (Ultra-)Short Recordings for Heart Rate Variability Measurements. PLoS One. 2015 Sep 28;10(9):e0138921. doi: 10.1371/journal.pone.0138921. eCollection 2015. PubMed 26414314 ↗
  • Thayer JF, Yamamoto SS, Brosschot JF. The relationship of autonomic imbalance, heart rate variability and cardiovascular disease risk factors. Int J Cardiol. 2010 May 28;141(2):122-31. doi: 10.1016/j.ijcard.2009.09.543. Epub 2009 Nov 11. PubMed 19910061 ↗
  • Heart rate variability: standards of measurement, physiological interpretation and clinical use. Task Force of the European Society of Cardiology and the North American Society of Pacing and Electrophysiology. Circulation. 1996 Mar 1;93(5):1043-65. No abstract available. PubMed 8598068 ↗
  • Shaffer F, Ginsberg JP. An Overview of Heart Rate Variability Metrics and Norms. Front Public Health. 2017 Sep 28;5:258. doi: 10.3389/fpubh.2017.00258. eCollection 2017. PubMed 29034226 ↗

Individual participant data

Plan to share: No

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Start is estimated for May 2026; primary completion for Aug 2026, 3 months later.

How these figures are worked out, and which studies are left out of them.

Registered
Apr 6, 2026
First posted
Apr 15, 2026
StartEst.
May 1, 2026
Primary completionEst.
Aug 31, 2026
CompletionEst.
Sep 15, 2026
Last update
Apr 15, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Apr 15, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT07531992
Lead sponsor
Sinop University
Responsible party
SEFA HAKTAN HATIK (Assistant professor, Sinop University) — Principal investigator
First posted
Apr 15, 2026
Start date
May 1, 2026 (estimated)
Primary completion
Aug 31, 2026 (estimated)
Completion
Sep 15, 2026 (estimated)
Last update
Apr 15, 2026

Study contacts

Sefa Haktan Hatık, PhD
Contact
haktanhtk@gmail.com
+90 368 271 55 28

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is not yet recruiting, as verified in Apr 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion